• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

Comprehensive Overview of 7-Bromo-2-chlorothieno[3,2-d]pyrimidin-4-amine (CAS No. 1308690-60-9)

7-Bromo-2-chlorothieno[3,2-d]pyrimidin-4-amine is a heterocyclic compound with significant potential in pharmaceutical and agrochemical research. Its molecular structure, featuring a thienopyrimidine core substituted with bromo and chloro functional groups, makes it a versatile intermediate for synthesizing bioactive molecules. Researchers are increasingly interested in this compound due to its role in developing kinase inhibitors and antimicrobial agents, aligning with current trends in drug discovery and precision medicine.

The compound's CAS No. 1308690-60-9 is a unique identifier widely used in chemical databases and regulatory documentation. Its thienopyrimidine scaffold is a hotspot in medicinal chemistry, as it mimics purine bases, enabling interactions with biological targets like enzymes and receptors. This property has spurred investigations into its applications for cancer therapy and infectious disease treatment, topics frequently searched in academic and industry circles.

From a synthetic perspective, 7-Bromo-2-chlorothieno[3,2-d]pyrimidin-4-amine offers modular reactivity. The bromo group facilitates cross-coupling reactions (e.g., Suzuki or Buchwald-Hartwig), while the chloro substituent allows nucleophilic substitutions. Such flexibility is critical for creating diversified compound libraries, a strategy emphasized in high-throughput screening and fragment-based drug design—key areas in modern pharmaceutical R&D.

Environmental and safety profiles of this compound are also under scrutiny, reflecting broader societal concerns about green chemistry and sustainable synthesis. Researchers are exploring catalytic methods to reduce waste generation during its production, addressing queries like "eco-friendly heterocyclic synthesis" often seen in search engine trends.

In summary, 7-Bromo-2-chlorothieno[3,2-d]pyrimidin-4-amine (CAS 1308690-60-9) exemplifies the intersection of structural ingenuity and therapeutic potential. Its relevance to kinase inhibitor development, antimicrobial resistance, and sustainable chemistry ensures continued interest across scientific disciplines.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)